Trigeminal Nerve Diseases: Clinical Trials

10 trials for Trigeminal Nerve Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 withdrawn, 2 completed, 2 unknown, 1 active not recruiting. 10 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Withdrawn 4, Completed 2, Unknown 2, Active not recruiting 1, Terminated 1
Phase 24Withdrawn 2, Active not recruiting 1, Completed 1

Follow Trigeminal Nerve Diseases: new trials by email Literature Review of Trigeminal Nerve Diseases trials Research Report on Trigeminal Nerve Diseases

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia
Botulinum toxin A, Isotonic saline - Trigeminal Neuralgia
Phase 3UnknownHenrik Schytz802023-11-012024-03-18
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
BIIB074, Placebo - Trigeminal Neuralgia
Phase 3WithdrawnBiogen2023-04-192023-05-06
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
BIIB074, Placebo - Trigeminal Neuralgia
Phase 3WithdrawnBiogen2023-03-012023-05-06
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Basimglurant, Placebo - Trigeminal Neuralgia
Phase 2 / Phase 3Active not recruitingNoema Pharma AG1662022-01-112026-01-23
Botulinum Toxin Injections for Oral Neuropathic Pain
BOTOX®, Allergan, Placebo - Trigeminal Neuropathy, Traumatic
Phase 3CompletedAssistance Publique - Hôpitaux de Paris432019-04-042023-04-10
Botulinum Toxin for Trigeminal Neuralgia
Botulinum Toxin type A (intradermal / submucosal injection at pain area), Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved) - Trigeminal Neuralgia
Phase 3UnknownThe First Affiliated Hospital of Zhengzhou University1502017-11-072018-11-26
Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
ATNC05, Placebo - Atypical Facial Pain, Persistent Idiopathic Facial Pain
Phase 2 / Phase 3WithdrawnAllodynic Therapeutics, Inc2014-03-012014-03-13
A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia
Amifostine, CyberKnife stereotactic radiosurgery - Trigeminal Neuralgia
Phase 3TerminatedStanford University172008-09-012017-04-04
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia
Lamictal®, Tegretol® - Trigeminal Neuralgia
Phase 2 / Phase 3CompletedUniversity of Malaya212007-09-012010-06-29
Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception
laboratory pain assessment, transcranial magnetic stimulation - Pain, Trigeminal Neuralgia
Phase 2 / Phase 3WithdrawnMedical University of South Carolina2006-07-012012-04-30

Narrower conditions

Trigeminal Neuralgia (9)  ·  Chronic Pain (1)  ·  Complex Regional Pain Syndromes (1)  ·  Facial Pain (1)  ·  Neuralgia (1)  ·  Pain (1)  ·  Reflex Sympathetic Dystrophy (1)  ·  Trigeminal Nerve Injuries (1)

Broader conditions

Cranial Nerve Diseases (10)  ·  Facial Nerve Diseases (10)  ·  Facial Neuralgia (10)  ·  Mouth Diseases (10)  ·  Nervous System Diseases (10)  ·  Stomatognathic Diseases (10)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Autonomic Nervous System Diseases (1)  ·  Cranial Nerve Injuries (1)  ·  Craniocerebral Trauma (1)  ·  Neuromuscular Diseases (1)  ·  Pain (1)

Interventions

Botulinum Toxins, Type A (3)  ·  vixotrigine (2)  ·  2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (1)  ·  Amifostine (1)  ·  Carbamazepine (1)  ·  Injections, Intradermal (1)  ·  Lamotrigine (1)  ·  Radiosurgery (1)  ·  Sodium Chloride (1)  ·  Transcranial Magnetic Stimulation (1)

Sponsors

Biogen (2)  ·  Allodynic Therapeutics, Inc (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Henrik Schytz (1)  ·  Medical University of South Carolina (1)  ·  Noema Pharma AG (1)  ·  Stanford University (1)  ·  The First Affiliated Hospital of Zhengzhou University (1)  ·  University of Malaya (1)

Countries

United States (4)  ·  Denmark (2)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Poland (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Chuanjie Wu, MD (1)  ·  Clara Choi (1)  ·  Dr. Sameer Shaikh, MDSc. (1)  ·  Jeffrey J. Borckardt, Ph.D. (1)  ·  Scott Soltys (1)

Results publications

PMID 21621166

NIH funding

2016 (2), 2017 (1), K23NS050485 (1)